Noxopharm Limited Performance
| NOXOFDelisted Stock | USD 0.04 0.00 0.00% |
The company secures a Beta (Market Risk) of 0.0, which conveys not very significant fluctuations relative to the market. the returns on MARKET and Noxopharm are completely uncorrelated.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Noxopharm Limited has generated negative risk-adjusted returns adding no value to investors with long positions. Despite nearly stable basic indicators, Noxopharm is not utilizing all of its potentials. The current stock price disturbance, may contribute to mid-run losses for the stockholders. ...more
Noxopharm |
Noxopharm Relative Risk vs. Return Landscape
If you would invest 4.50 in Noxopharm Limited on November 16, 2025 and sell it today you would earn a total of 0.00 from holding Noxopharm Limited or generate 0.0% return on investment over 90 days. Noxopharm Limited is currently producing negative expected returns and takes up 0.0% volatility of returns over 90 trading days. Put another way, 0% of traded pink sheets are less volatile than Noxopharm, and 99% of all traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
Noxopharm Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Noxopharm for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Noxopharm Limited can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Noxopharm Limited is not yet fully synchronised with the market data | |
| Noxopharm Limited has some characteristics of a very speculative penny stock | |
| Noxopharm Limited has a very high chance of going through financial distress in the upcoming years | |
| The company reported the revenue of 5.43 M. Net Loss for the year was (18.67 M) with loss before overhead, payroll, taxes, and interest of (2.35 M). | |
| Noxopharm Limited has accumulated about 14.01 M in cash with (13.73 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.05, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 34.0% of the company outstanding shares are owned by corporate insiders |
Noxopharm Fundamentals Growth
Noxopharm Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Noxopharm, and Noxopharm fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Noxopharm Pink Sheet performance.
| Return On Equity | -0.58 | |||
| Return On Asset | -0.16 | |||
| Operating Margin | (1.80) % | |||
| Current Valuation | 22.3 M | |||
| Shares Outstanding | 292.24 M | |||
| Price To Book | 2.36 X | |||
| Price To Sales | 7.11 X | |||
| Revenue | 5.43 M | |||
| EBITDA | (18.33 M) | |||
| Cash And Equivalents | 14.01 M | |||
| Cash Per Share | 0.05 X | |||
| Total Debt | 160.62 K | |||
| Debt To Equity | 0.01 % | |||
| Book Value Per Share | 0.08 X | |||
| Cash Flow From Operations | (13.73 M) | |||
| Earnings Per Share | (0.03) X | |||
| Total Asset | 26.59 M | |||
About Noxopharm Performance
By analyzing Noxopharm's fundamental ratios, stakeholders can gain valuable insights into Noxopharm's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Noxopharm has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Noxopharm has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Noxopharm Limited, a drug development company, focuses on developing treatment options for a range of solid tumor cancers and septic shock in Australia and internationally. The company was incorporated in 2015 and is based in Chatswood, Australia. Noxopharm operates under Biotechnology classification in the United States and is traded on OTC Exchange.Things to note about Noxopharm Limited performance evaluation
Checking the ongoing alerts about Noxopharm for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Noxopharm Limited help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Noxopharm Limited is not yet fully synchronised with the market data | |
| Noxopharm Limited has some characteristics of a very speculative penny stock | |
| Noxopharm Limited has a very high chance of going through financial distress in the upcoming years | |
| The company reported the revenue of 5.43 M. Net Loss for the year was (18.67 M) with loss before overhead, payroll, taxes, and interest of (2.35 M). | |
| Noxopharm Limited has accumulated about 14.01 M in cash with (13.73 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.05, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 34.0% of the company outstanding shares are owned by corporate insiders |
- Analyzing Noxopharm's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Noxopharm's stock is overvalued or undervalued compared to its peers.
- Examining Noxopharm's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Noxopharm's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Noxopharm's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Noxopharm's pink sheet. These opinions can provide insight into Noxopharm's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment. You can also try the Portfolio Center module to all portfolio management and optimization tools to improve performance of your portfolios.
Other Consideration for investing in Noxopharm Pink Sheet
If you are still planning to invest in Noxopharm Limited check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Noxopharm's history and understand the potential risks before investing.
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals |